GSK Signs a Worldwide Development & Commercialization Collaboration with Merck KGaA, for $4.2B

 GSK Signs a Worldwide Development & Commercialization Collaboration with Merck KGaA, for $4.2B

GSK Signs a Worldwide Development & Commercialization Collaboration with Merck KGaA, for $4.2B

Shots:

  • Merck KGaA to receive $4.2B as total deal value, including $341.76M upfront, up to $3.8B milestones including R&D, regulatory and commercialization. GSK to get worldwide co-development and co-commercialization rights for Merck’s M7824 with 50/50 profit/cost sharing
  • The focus of the agreement is to strengthen GSK’s oncology portfolio in areas of immuno-oncology, cell therapy, cancer epigenetics and genetic medicine
  • Merck’s M7824 (bintrafusp alfa) is a bifunctional immunotherapy targeting TGF-β trap with anti-PD-L1 mechanism and is evaluated in P-I/II vs pembrolizumab in 700 patients with PD-L1 expressing advanced NSCLC

Click here read full press release/ article | Ref: GSK | Image:CNBC

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post